Harvard Bioscience, Inc
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing. Its portfolio spans proprietary instruments, systems, software, and consumables sold to academic labs, pharma/biotech companies, CROs, hospitals, and government research institutions worldwide.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBehavioral, respiratory, organ-based, and surgical systems used in preclinical research and testing.
Instruments and accessories for tissue, cell, and molecular biology workflows.
Resold instruments, accessories, and consumables from other manufacturers.
Products
Reported · share of revenue- Instruments Equipment Software and Accessories90.4 %
- Service Maintenance and Warranty Contracts9.6 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to pharmaceutical and biotechnology companies, universities, hospitals, government laboratories, and CROs. Demand is driven by research budgets, preclinical study activity, and the need for specialized tools that support discovery, translational research, and therapy development.
Buy research and preclinical systems for drug and therapy discovery, screening, and translational studies.
Buy instruments and accessories for basic research, physiology, and life-science education.
Buy high-throughput testing and monitoring systems for outsourced preclinical programs.
Buy specialized research platforms for funded biomedical and defense-related studies.
Buy tools for translational and disease-model research supporting therapy development.
Strategy
Management is repositioning the company around translational medicine and NAMs, using its preclinical base to bridge in vivo and in vitro research. The strategy emphasizes new product introductions, more consumables and software, and tighter operations through manufacturing consolidation, portfolio rationalization, and bolt-on acquisitions.
Positions the company for industry demand shifting toward NAMs and more human-relevant models.
Raises recurring revenue and can improve margin stability versus one-time instrument sales.
New platforms support growth and help defend pricing in specialized niches.
Cost discipline is needed to support profitability in a soft demand environment.
Geography
Q1/2026Harvard Bioscience operates in the United States, Europe, and China, selling through both direct and distributor channels. The company is exposed to cross-border trade friction, especially U.S.-China tariffs, and also relies on overseas sourcing and foreign-currency-denominated costs, which affect margins and reported results.
Share of the revenue the company reports by geography.
Risks
The business is exposed to cyclical research spending, especially at academic institutions and CROs, and management has already cited softening demand. It also faces tariff pressure, supply-chain cost inflation, refinancing and covenant risk, Nasdaq listing risk, and impairment risk tied to goodwill and other long-lived assets.
- Softening demand from academic research institutions and CROsImpact: HighLikelihood: Medium
These customers depend on grant and project funding, so purchases can be delayed when budgets tighten.
Exposure: Revenue and order timing
- Tariffs and trade restrictions, especially between the U.S. and ChinaImpact: HighLikelihood: Medium
The company sells and sources internationally, so tariffs can raise costs and reduce demand.
Exposure: Gross margin and supply chain
- Debt covenant and refinancing complianceImpact: HighLikelihood: Low
The company disclosed covenant waivers and refinancing milestone issues, which can limit financial flexibility.
Exposure: Liquidity and capital structure
- Nasdaq minimum bid price noncomplianceImpact: HighLikelihood: Low
Failure to regain compliance could lead to delisting and reduce access to capital and trading liquidity.
Exposure: Capital markets access
- Goodwill and long-lived asset impairmentImpact: High
Weak demand and lower operating profits increase the chance that carrying values exceed fair value.
Exposure: Balance sheet and earnings
Accounting
Judgemental itemsDirect versus distributor sales can shift timing and margin profile across periods.
Impact: Quarterly revenue comparability and gross margin
Management disclosed impairment indicators and a large goodwill charge in 2025.
Impact: Non-cash operating expense and balance sheet carrying values
International operations create euro and pound exposure in revenue and costs.
Impact: Reported revenue, expenses, and comprehensive income
Waivers and amendments affect classification, interest expense, and liquidity disclosures.
Impact: Financing costs and going-concern/liquidity assessment
Similar listed companies
Publicly listed companies with a comparable business focus.
Rapid Micro Biosystems, Inc
RPID · Laboratory Analytical Instruments
Rapid Micro Biosystems is a U.S.-based life sciences technology company that develops the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.
Harvard Apparatus Regenerative Technology, Inc.
HRGN · Surgical & Medical Instruments & Apparatus
Thermo Fisher Scientific Inc
TMO · Measuring & Controlling Devices, NEC
Thermo Fisher Scientific is a U.S.-based life sciences and laboratory company organized around four segments: Life Sciences Solutions, Analytical Instruments,…
Mesa Laboratories, Inc
MLAB · Industrial Instruments For Measurement, Display, and Control
Mesa Laboratories designs and manufactures life sciences tools and critical quality control solutions used in regulated pharmaceutical, healthcare, and medical device applications.
Simulations Plus, Inc.
SLP · Services-Computer Integrated Systems Design
Cryoport, Inc.
CYRX · Pharmaceutical Preparations
Last updated: 24/09/2026